RSNA 2007 

Abstract Archives of the RSNA, 2007


SSC07-02

Does Bone Scan Add Any Incremental Value to 18FDG PET/CT in Restaging Patients with Breast Carcinoma?

Scientific Papers

Presented on November 26, 2007
Presented as part of SSC07: Nuclear Medicine (PET/CT in Breast and Genitourinary Malignancies)

Participants

Mohei Moustafa Abouzied MD, Presenter: Nothing to Disclose
Mahmud Tuli MD, Abstract Co-Author: Nothing to Disclose
Abdelaziz Alsugair, Abstract Co-Author: Nothing to Disclose
Naima Alblushi MD, Abstract Co-Author: Nothing to Disclose
Ayman Rifai, Abstract Co-Author: Nothing to Disclose

PURPOSE

This is a retrospective study with prospective design to test our hypothesis; whether bone scan would be of value in restaging breast cancer patients along with 18F FDG-PET/CT.

METHOD AND MATERIALS

46 patients with breast cancer have been identified in our database that had 18F FDG-PET/CT study. 19/46 female patients (mean age of 52 years range 31-91 years) have met our inclusion criteria; namely biopsy proven breast cancer, bone scan and 18F FDG-PET/CT within 4 weeks of each other. Also, radiological and or follow-up for at least six months. Two nuclear medicine physicians reviewed each modality blinded to the results of the other modality

RESULTS

Both modalities were concordant in 13 patients in excluding bone metastases. Bone scan was equivocal in one patient in whom 18F FDG-PET/CT was conclusive in excluding bone metastases, a result that was confirmed clinically and by a second radiologic modality. Furthermore, in 5 other patients both modalities were concordant in showing multiple bone metastatic disease. However, in 4/5 patients 18F FDG-PET/CT revealed more bony lesions in addition to visceral metastases involving the lung, liver, lymph nodes and soft tissue local recurrence.

CONCLUSION

18F FDG-PET/CT is sufficient enough in the metastatic work up of breast cancer patients by accurately revealing the extent of bone metastasis in addition to documenting non skeletal metastases.

CLINICAL RELEVANCE/APPLICATION

FDG PET/CT is a valuable tool in restaging patients with breast cancer by accurately depicting both visceral and the skeletal metastases

Cite This Abstract

Abouzied, M, Tuli, M, Alsugair, A, Alblushi, N, Rifai, A, Does Bone Scan Add Any Incremental Value to 18FDG PET/CT in Restaging Patients with Breast Carcinoma?.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5015400.html